Steven on User Fees in Roll Call Daily

by Steven Grossman | Mar 28, 2025 | Uncategorized | 0 comments

Permission is granted to reprint or recirculate this column, as long as attribution is made to FDA Matters and the author.

Targeting FDA user fees would leave agency gutted, experts say

Steven Grossman, a regulatory consultant at HPS Group and author of the FDA Matters newsletter, said in an email to CQ Roll Call that his concerns about the future of the user fee program have grown since the Trump administration took over.

“The risk of dramatically different medical product user fee programs — or none at all — has gone from blue (general risk) to at least yellow (significant risk),” he wrote. “If somebody suggested orange (high risk), I would not say they are exaggerating.” Read Full Article

FDA Matters provides short-form analysis of FDA policy and regulatory issues. We know you are busy, so we publish 1 to 2 columns per week, each a 3-5 minute read.

FDA Matters does not report the news….we provide analysis of what’s behind the news.

FDA Matters advocates for a more effective, efficient, and fair FDA.

FDA Matters has been featured in:

Steven A. Grossman, JD, is the founder and author of FDA Matters. Read more about Steven here.